基本信息:
- 专利标题： Monoclonal antibody against estrogen stimulated leucine aminopeptidase
- 专利标题（中）：针对雌激素刺激的亮氨酸氨基肽酶的单克隆抗体
- 申请号：US10705991 申请日：2003-11-12
- 公开(公告)号：US20040106143A1 公开(公告)日：2004-06-03
- 发明人： Gabriel Pulido-Cejudo
- 优先权： CA2,267,481 20000330
- 主分类号： C12Q001/68
- IPC分类号： C12Q001/68 ; G01N033/574
摘要：
The identification and characterization of risk factors and their molecular implications in the pathophysiology of human diseases such as cancer is essential for designing efficient diagnostic assays and therapeutic compounds. Estrogenic steroids, under normal physiological conditions, have been shown to play a critical function in several tissues. The response of such a variety of tissues to estrogen stimulation can explain in part its active role in the development and progression of different human diseases, particularly Breast Cancer. Searching for estrogen-responding cellular factors in parental cells of primary human breast carcinomas obtained from tumour biopsies an isoenzyme of putative Leucine Aminopeptidase (LAPase; EC 3.4.11.1) was identified. Results have demonstrated that this marker is found to be elevated in the sera of women with invasive ductal and metastatic carcinomas. A monoclonal antibody against this cellular marker have been produced. This invention refers to the use of LAPase monoclonal antibodies for first line confirmatory blood-based testing for Breast Cancer.
摘要（中）：
识别和表征危险因素及其在人类疾病如癌症的病理生理学中的分子意义对于设计有效的诊断测定和治疗化合物至关重要。 在正常生理条件下，雌激素类固醇已显示在几种组织中起关键作用。 这种多种组织对雌激素刺激的反应可以部分解释其在不同人类疾病，特别是乳腺癌的发展和进展中的积极作用。 在从肿瘤活检中获得的原代人乳腺癌的亲代细胞中寻找雌激素反应性细胞因子，鉴定出推定的亮氨酸氨基肽酶（LAPase; EC 3.4.11.1）的同工酶。 结果表明，这种标志物被发现在具有浸润性导管和转移性癌症的妇女的血清中升高。 已经产生了针对该细胞标记物的单克隆抗体。 本发明涉及使用LAPase单克隆抗体进行乳腺癌一线验证性血液检测。